Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Cubist Pharmaceuticals to Announce Second Quarter 2008 Financial Results on Thursday, July 17, 2008.


Conference Call to be Held at 5:00 p.m. EDT EDT
abbr.
Eastern Daylight Time


EDT Eastern Daylight Time

EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York

EDT 
 

LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: CBST CBST Center for Biophotonics Science and Technology
CBST Congregation Beth Simcha Torah (NYC)
CBST Complete Binary Search Tree
) will issue its second quarter 2008 financial results at 4:00 p.m. EDT on Thursday, July 17th, 2008. In connection with this announcement, Cubist will host a conference call and live audio webcast (with slides) at 5:00 p.m. EDT that same day to discuss its second quarter financial results, business activities and financial outlook.

As always, the quarterly earnings call will be available via phone and webcast. The phone call dial-in information is listed below. To access the webcast, please log on to the Cubist website at www.cubist.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available on Cubist's website beginning approximately three hours after the call.
[TABLE OMITTED]


About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN[R](daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase II clinical trials for the prevention of blood loss during cardiothoracic surgery, and pre-clinical programs that address unmet medical needs in Gram-positive infections, Gram-negative infections, CDAD CDAD Clostridium Difficile-Associated Diarrhea
CDAD Component Data Administrator
 (Clostridium clostridium

Any of the rod-shaped, usually gram-positive bacteria (see gram stain) that make up the genus Clostridium. They are found in soil, water, and the intestinal tracts of humans and other animals. Some species grow only in the complete absence of oxygen.
 difficile-associated diarrhea), and HCV HCV
abbr.
hepatitis C virus


HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus.
 (Hepatitis C infections). Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Financial report
Date:Jul 1, 2008
Words:282
Previous Article:Wizzard Media Signs Podcast Publishing and Advertising Deal with Spike TV.
Next Article:NGAS Resources to Present at Collins Stewart Investor Conference.
Topics:



Related Articles
Cubist Pharmaceuticals Reports Second Quarter 2006 Results; Total Revenues $47.8 Million; Net Product Revenues $45.7 Million, up 78% Vs. 2Q05; GAAP...
Cubist Pharmaceuticals to Announce First Quarter 2008 Financial Results on Thursday, April 17, 2008.
Cubist Pharmaceuticals Q1 2008 Revenues up 48%; Net Income up 220%: Total Revenues $88.3 Million; Net Product Revenues $87.9 Million.
Dyax Corp. Announces First Quarter 2008 Financial Results.
Cubist Pharmaceuticals Reports First $100 Million Revenue Quarter; Q2 2008 Total Revenues $101.8 Million; Total Net Product Revenues $101.4 Million.
Dyax Corp. Announces Second Quarter 2008 Financial Results.
CUBIST REPORTS FIRST $100 MILLION REVENUE QUARTER.
Cubist Pharmaceuticals to Announce Third Quarter 2008 Financial Results on Thursday, October 16, 2008.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles